Celldex Therapeutics (NASDAQ:CLDX) Hits New 1-Year Low - What's Next?

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low as $22.08 and last traded at $22.37, with a volume of 373325 shares trading hands. The stock had previously closed at $23.29.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CLDX. HC Wainwright reiterated a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $62.25.

Celldex Therapeutics Trading Up 1.8 %

The business's 50 day moving average price is $25.02 and its 200-day moving average price is $30.24. The company has a market cap of $1.45 billion, a price-to-earnings ratio of -8.53 and a beta of 1.60.

Institutional Trading of Celldex Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP lifted its stake in shares of Celldex Therapeutics by 14.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company's stock worth $314,190,000 after buying an additional 1,167,659 shares during the last quarter. Vanguard Group Inc. increased its position in Celldex Therapeutics by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company's stock worth $98,098,000 after acquiring an additional 12,213 shares during the period. Bellevue Group AG increased its position in Celldex Therapeutics by 3.4% during the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company's stock worth $104,404,000 after acquiring an additional 100,000 shares during the period. Geode Capital Management LLC increased its position in Celldex Therapeutics by 0.4% during the third quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company's stock worth $52,372,000 after acquiring an additional 6,557 shares during the period. Finally, Jennison Associates LLC increased its position in Celldex Therapeutics by 32.0% during the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company's stock worth $45,017,000 after acquiring an additional 321,325 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.